Semaglutide and liraglutide are associated with reduced AUD and SUD-related hospitalization risks, unlike other GLP-1 ...
In the univariate analysis, those on an SGLT-2i/GLP-1 RA had a reduced risk for mortality, incident MI, and composite. (HealthDay News) — For patients with ischemic stroke, sodium-glucose ...
In a study of around 228,000 people in Sweden who had alcohol use disorder, researchers found that people who were taking a ...
A new weight loss drug target may help reduce appetite and burn calories without causing sickness, research suggests. The ...
With the rising popularity of telehealth providers offering GLP-1 medications like Ozempic, the terminology can get confusing ...
Pemvidutide is a promising GLP-1/glucagon dual receptor agonist that focuses on fundamental metabolic processes to stimulate ...
Amgen has rebuffed claims made by an analyst suggesting that its obesity drug MariTide is associated with reductions in bone ...
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer (EO-CRC) in patients with diabetes regardless of weight, according to a study ...
Just seven months after unveiling with $290 million, obesity biotech Metsera is back with another $215 million.
WEDNESDAY, Nov. 13, 2024 (HealthDay News) -- The blockbuster GLP-1 drug semaglutide ( Ozempic, Wegovy) could curb drinking ...
Early studies show a drug can effectively 'switch on' particular cells within the nervous system that play an important role ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback